Screener / SEC EDGAR /CIK 0001585364 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

PERRIGO Co plc PRGO

Compare with peers Embed
What it said it expected, against what it reported

No target with a reported result yet

Releases of the last 3 years

The numbers PRGO said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Diluted EPS (company-defined)
Fiscal 2026
Given $2.00 to $2.30 release Feb 26, 2026
– No standard number
The company's words
FY2026 'All In' adjusted diluted EPS range outlook is $2.00 to $2.30. release Feb 26, 2026
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $2.90 to $3.10 release Aug 6, 2025
Lowered $2.70 to $2.80 release Nov 5, 2025
– No standard number
The company's words
Reaffirms Full Year 2025 Adj. EPS Target Range of $2.90 - $3.10 release Aug 6, 2025
Due primarily to infant formula industry dynamics and soft OTC consumption trends, the Company is updating its 2025 outlook to: … Adjusted EPS of $2.70 to $2.80, equating to growth of 5% to 9% year-over-year. release Nov 5, 2025
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $2.50 to $2.65 release Feb 27, 2024
Kept $2.50 to $2.65 release May 7, 2024
Kept $2.50 to $2.65 release Aug 2, 2024
Kept $2.50 to $2.65 release Nov 6, 2024
– No standard number
The company's words
The Company also issues its fiscal 2024 adjusted diluted EPS range outlook of $2.50-$2.65 (see Fiscal 2024 Outlook section below), resulting in mid-teens adjusted diluted EPS growth, excluding infant formula. release Feb 27, 2024
The Company also reaffirms its fiscal 2024 adjusted diluted EPS range outlook of $2.50-$2.65. release May 7, 2024
The Company reaffirms its fiscal 2024 adjusted diluted EPS outlook of $2.50-$2.65, as increased profitability from faster than anticipated recovery in the infant formula business, improved product mix and lower selling expenses are expected to be offset by flow-through from the updated net sales outlook. release Aug 2, 2024
Fiscal Year 2024 Outlook: … The Company reaffirms its adjusted diluted EPS outlook of $2.50 to $2.65. release Nov 6, 2024
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2024-02-27), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRGO/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.